Showing 4081-4090 of 5911 results for "".
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/Inflammasome Therapeutics, developer of a new class of inflammasome inhibitor drugs called Kamuvudines, announced the FDA has granted approval for the opening of a phase 1/2 clinical trial of the company’s drug for the treatment of geographic atrophy (GA). This is the first clinical tr
- Injectsense and Injectpower Secure $9.4M to Support Injectsense's First-in-Human Studies for Sensors that Continuously Measure IOPhttps://modernod.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/Injectsense and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices—smaller than a grai
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener
- Orcam Technologies Unveils Orcam Read 3 AI-Driven Solution for People with Low Vision and Visual Impairmentshttps://modernod.com/news/orcam-technologies-unveils-orcam-read-3-ai-driven-solution-for-people-with-low-vision-and-visual-impairments/2481965/OrCam Technologies has introduced the OrCam Read 3, which is designed to improve the way people with vision loss and reading difficulties interact with visual materials. User point the device at a book, computer screen, product packaging or any text, and the AI technology will loudly and cle
- OIG Publishes General Compliance Program Guidance for the Health Care Industryhttps://modernod.com/news/oig-publishes-general-compliance-program-guidance-for-the-health-care-industry/2481964/According to an advisory from law firm Arnold & Porter, on November 6, the Department of Health and Human Services Office of Inspector General (OIG) released a
- Research Unveils Potential Breakthrough in Diabetic Retinopathy Treatmenthttps://modernod.com/news/research-unveils-potential-breakthrough-in-diabetic-retinopathy-treatment/2481962/Researchers from Washington University in St. Louis have discovered a potential new treatment approach to diabetic retinopathy. Diabetic retinopathy’s enigma unfolds with the role of microglia, immune cells resident in the retina. When confronted with high blood glucose levels, th
- Study: Racial Disparities in Glaucoma Care Persist, Regardless of Socioeconomic Statushttps://modernod.com/news/study-racial-disparities-in-glaucoma-care-persist-regardless-of-socioeconomic-status/2481961/Many studies have shown that glaucoma is more common and more severe in Black and Hispanics than in Whites, but less is known about the impact of racial differences and socioeconomic status on vision loss and individual utilization of health care resources among glaucoma patients, according
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- Outlook Therapeutics Provides Update on Type A Meetings with FDA for Wet AMD Product Candidatehttps://modernod.com/news/outlook-therapeutics-provides-update-on-type-a-meetings-with-fda-for-wet-amd-product-candidate/2481959/Outlook Therapeutics announced that it has completed the requested Type A Meetings with the FDA to discuss the complete response letter (CRL) dated August 29, 2023 regarding the biologics license application (BLA) for ONS-5010, an investigational ophthalmi
- World’s First Whole Eye & Partial Face Transplant Performed at NYU Langone Healthhttps://modernod.com/news/worlds-first-whole-eye-partial-face-transplant-performed-at-nyu-langone-health/2481958/A surgical team from NYU Langone Health performed the world’s first whole-eye and partial-face transplant for a 46-year-old military veteran from Arkansas who survived a work-related high-voltage electrical accident. The surgery included transplanting the entire left eye and a portion of th